Glaxo Receives Approval For Flonase
The US Food and Drug Administration has approved Glaxo's Flonase (fluticasone propionate) nasal spray for the treatment of seasonal and perenial allergic rhinitis. The company added that it should not be used for nonallergic rhinitis since there is no data to support its use.
The starting dose is two sprays in each nostril once-daily. Each spray delivers 50mcg of the drug. For maintenance treatment, said the company, the dose may be reduced to a total of 100mcg per day. Patients should use Flonase at regular intervals as directed, added Glaxo, since its effectiveness depends on its regular use.
The drug was effective and well tolerated at recommended doses in US studies involving more than 2,400 patients. Side effects included nasal burning, irritation, nosebleeds and headaches, which are "similar to those seen with other widely- used prescription nasal sprays," said the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze